

APPENDIX B (2019;4:A1703)

APPENDIX B. AANTAL OVERSCHREVEN MIA MELDINGEN, GECATEGORISEERD NAAR TYPE MONITORING EN ERNST CONFORM DE G-STANDAARD. GEWOGEN GEMIDDELDE OP BASIS VAN HET AANTAL EN HET PERCENTAGE.

| | <i>Ernst</i> | <i>Aantal meldingen per type monitoring</i> | <i>% overschreven meldingen per type monitoring</i> |
|--|---------------------------------------|---|---|
| Monitoring van labwaarden | | | |
| | <i>Glucose</i> | 535 | 96% |
| BETABLOKKERS NIET-SELECTIEF + INSULINE | D | 535 | 96% |
| | <i>Kalium</i> | 2082 | 96% |
| RAAS-REMmers + KALIUM(SPAARDERS) | F | 2082 | 96% |
| | <i>Geneesmiddelen (TDM)</i> | 441 | 94% |
| THEOFYLLINE + CYP1A2-REMmers | F | 7 | 100% |
| DIGOXINE + VERAPAMIL/DILTIAZEM | D | 24 | 100% |
| CICLOSPORINE + CYP3A4-REMmers/P-GP-REMmers | D | 45 | 100% |
| FENYTOINE + ONCOLOGISCHE MIDDELEN (CYTOSTATISCH) | D | 5 | 100% |
| FENYTOINE + FOLIUMZUUR | D | 4 | 100% |
| VALPROINEZUUR + ONCOLOGISCHE MIDDELEN (CYTOSTAT.) | D | 4 | 100% |
| CLOZAPINE + FLUVOXAMINE/FLUOXETINE/SERTRALINE | D | 3 | 100% |
| LITHIUM + DIURETICA | D | 4 | 100% |
| HALOPERIDOL + INDUCTOREN | D | 202 | 94% |
| THEOFYLLINE + ERYTROMYCINE | D | 46 | 93% |
| DIGOXINE + ERYTRO/CLARITRO/ROXI/AZITROMYCINE | D | 91 | 90% |
| ANTIDEPRESSIVA TRICYCLISCH + CYP2D6-REMmers/SSRI's | D | 3 | 67% |
| TACROLIMUS + SEVELAMEER | E | 2 | 50% |
| TACROLIMUS + AMIODARON | E | 1 | 0% |
| | <i>INR</i> | <i>Aantal meldingen per type monitoring</i> | <i>% overschreven meldingen per type monitoring</i> |
| | | 616 | 98% |
| CUMARINES + VITAMINE K | D | 15 | 100% |
| CUMARINES + COTRIMOXAZOL | D | 10 | 100% |
| CUMARINES + SSRI's/VENLAFAXINE/DULOXETINE/TRAZODON | D | 8 | 100% |
| CUMARINES + RIFAMPICINE/RIFABUTINE/RIFAXIMINE | D | 2 | 100% |
| CUMARINES + ALLOPURINOL | D | 2 | 100% |
| CUMARINES + MICONAZOL ORAAL/VAGINAAL/CUTAAN | E | 1 | 100% |
| CUMARINES + (ES)OMEPRAZOL | D | 137 | 99% |
| CUMARINES + ANTIBIOTICA (EX. COTRIM/METRON/CEFAM.) | D | 362 | 98% |
| CUMARINES + AMIODARON/PROPAFENON | D | 79 | 97% |
| | <i>Nierfunctie (serum creatinine)</i> | 1538 | 98% |
| STATINES + COLCHICINE | E | 2 | 100% |
| CICLOSPORINE + CYP3A4-REMmers/P-GP-REMmers | D | 45 | 100% |
| RAAS-REMmers + NSAID's | D | 1467 | 98% |

| | | | |
|--|---------------------|-----------|-------------|
| CICLOSPORINE + COTRIMOXAZOL/TRIMETHOPRIM | D | 24 | 92% |
| | Leverfunctie | 2 | 100% |
| STATINES + COLCHICINE | E | 2 | 100% |
| | Natrium | 59 | 95% |
| SSRI'S/VENLAFAXINE/DULOXETINE + THIAZIDES | E | 2 | 100% |
| CARBAMAZEPINE/OXCARBAZEPINE + DIURETICA | E | 57 | 95% |

Monitoren op klinisch effect/toxiciteitsverschijnselen

| | | ECG bewaking | 3596 | 96% |
|---|---|---|---|------------|
| | | | | |
| DIGOXINE + VERAPAMIL/DILTIAZEM | D | 24 | 100% | |
| QT-VERLENGERS (WEL TDP) + QT-VERLENGERS (WEL TDP) | F | 1735 | 96% | |
| QT-VERLENGERS (WEL TDP) + QT-VERLENGERS (WEL TDP) | F | 1735 | 96% | |
| DIGOXINE + AMIODARON | D | 81 | 95% | |
| DILTIAZEM/VERAPAMIL + CYP3A4-REMmers/Cimetidine | F | 20 | 90% | |
| TACROLIMUS + AMIODARON | E | 1 | 0% | |
| | | 5595 | 98% | |
| Bloeddruk monitoring | | | | |
| ADRENALINE + BETABLOKKERS | E | 40 | 100% | |
| RAAS-REMmers + DIURETICA | D | 1738 | 99% | |
| RAAS-REMmers + NSAID's | D | 1467 | 98% | |
| DIURETICA + NSAID's | D | 2310 | 98% | |
| BETABLOKKERS + VERAPAMIL/DILTIAZEM | E | 20 | 95% | |
| DILTIAZEM/VERAPAMIL + CYP3A4-REMmers/Cimetidine | F | 20 | 90% | |
| | | 5287 | 97% | |
| Combinatie vermijden | | | | |
| CUMARINES + MICONAZOL ORAAL/VAGINAAL/CUTAAN | E | 1 | 100% | |
| CUMARINES + COTRIMOXAZOL | D | 10 | 100% | |
| STATINES + COLCHICINE | E | 2 | 100% | |
| DOPAMINERGE MIDDELEN + ANTI PSYCHOTICA | D | 6 | 100% | |
| THEOFYLLINE + CYP1A2-REMmers | F | 7 | 100% | |
| ADRENALINE + BETABLOKKERS | E | 40 | 100% | |
| COLCHICINE + CYP3A4-REMmers | F | 2 | 100% | |
| RIFABUTINE + CYP3A4-REMmers | D | 22 | 100% | |
| DIURETICA + NSAID's | D | 2310 | 98% | |
| | | Aantal meldingen per type monitoring | % overschreven meldingen per type monitoring | |
| Ernst | | | | |
| CORTICOSTEROÏDEN + INDUCTOREN | D | 214 | 97% | |
| QT-VERLENGERS (WEL TDP) + QT-VERLENGERS (WEL TDP) | F | 1735 | 96% | |
| BETABLOKKERS NIET-SELECTIEF + INSULINE | D | 535 | 96% | |
| BETABLOKKERS + VERAPAMIL/DILTIAZEM | E | 20 | 95% | |
| SIMVASTATINE/ATORVASTATINE + CYP3A4-REMmers | E | 139 | 94% | |
| THEOFYLLINE + ERYTROMYCINE | D | 46 | 93% | |
| ITRA/KETO/POSACONAZOL + SECRETIEREMMERS | D | 41 | 93% | |
| CICLOSPORINE + COTRIMOXAZOL/TRIMETHOPRIM | D | 24 | 92% | |
| DOPAMINERGE MIDDELEN + ANTI-EMETICA (ANTIDOPAMIN.) | D | 11 | 91% | |
| DIGOXINE + ERYTRO/CLARITRO/ROXI/AZITROMYCINE | D | 91 | 90% | |
| DILTIAZEM/VERAPAMIL + CYP3A4-REMmers/Cimetidine | F | 20 | 90% | |
| VALPROINEZUUR + CARBAPENEMS | D | 10 | 90% | |

| | | | |
|--|---|-------------|------------|
| TACROLIMUS + AMIODARON | E | 1 | 0% |
| <i>Dosisaanpassing/Langzaam titreren</i> | | 1890 | 99% |
| LAMOTRIGINE + VALPROINEZUUR | E | 3 | 100% |
| CLOZAPINE + FLUVOXAMINE/FLUOXETINE/SERTRALINE | D | 3 | 100% |
| COLCHICINE + CYP3A4-REMMERS | F | 2 | 100% |
| RIFABUTINE + CYP3A4-REMMERS | D | 22 | 100% |
| STATINES + GEMFIBROZIL | E | 1 | 100% |
| RAAS-REMMERS + DIURETICA | D | 1738 | 99% |
| DIGOXINE + AMIODARON | D | 81 | 95% |
| BETABLOKKERS + VERAPAMIL/DILTIAZEM | E | 20 | 95% |
| DILTIAZEM/VERAPAMIL + CYP3A4-REMMERS/CIMETIDINE | F | 20 | 90% |
| <i>Risicovermijdende maatregelen</i> | | 346 | 94% |
| KALIUMZOUTEN + KALIUMSPARENDE DIURETICA | F | 319 | 94% |
| KETANSERINE + DIURETICA (K-VERLIEZEND) | F | 27 | 93% |
| <i>Staand of zittend medicatie innemen</i> | - | - | - |
| <i>Kalium suppleren of kalium-besparend diureticum geven</i> | | 27 | 93% |
| KETANSERINE + DIURETICA (K-VERLIEZEND) | F | 27 | 93% |
| <i>Maagbescherming (PPI's)</i> | - | - | - |
| <i>De momenten van inname scheiden</i> | - | - | - |
| <i>Anders</i> | | 58 | 93% |
| DOPAMINERGE MIDDELEN + ANTIPSYCHOTICA | D | 6 | 100% |
| ITRA/KETO/POSACONAZOL + SECRETIEREMMERS | D | 41 | 93% |
| DOPAMINERGE MIDDELEN + ANTI-EMETICA (ANTIDOPAMIN.) | D | 11 | 91% |